Cutaneous adverse effects of the immune checkpoint inhibitors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Macdonald, 2015, Cutaneous adverse effects of targeted therapies, J Am Acad Dermatol, 72, 221, 10.1016/j.jaad.2014.07.033
Greenwald, 2005, The B7 family revisited, Annu Rev Immunol, 23, 515, 10.1146/annurev.immunol.23.021704.115611
Zimmer, 2012, Side effects of systemic oncological therapies in dermatology, J Dtsch Dermatol Ges, 10, 475
Voskens, 2013, The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from ipilimumab network, PLoS One., 8, e57345, 10.1371/journal.pone.0053745
Jaber, 2006, Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent, Arch Dermatol, 142, 166, 10.1001/archderm.142.2.166
Minkis, 2013, The risk of rash associated with ipilimumab in patients with cancer: a systemic review of the literature and meta-analysis, J Am Acad Dermatol, 69, e121, 10.1016/j.jaad.2012.12.963
Gogas, 2006, Prognostic significance of autoimmunity during treatment of melanoma with interferon, N Engl J Med, 354, 709, 10.1056/NEJMoa053007
Nordlund, 1983, Vitiligo in patients with metastatic melanoma: a good prognostic sign, J Am Acad Dermatol, 9, 689, 10.1016/S0190-9622(83)70182-9
Pintova, 2013, Sweet׳s syndrome in a patient with metastatic melanoma after ipilimumab therapy, Melanoma Res, 23, 498, 10.1097/CMR.0000000000000017
Kyllo, 2013, Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma, J Am Acad Dermatol, 70, e85, 10.1016/j.jaad.2013.11.022
Ross, 2013, Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab, J Am Acad Dermatol, 69, e272, 10.1016/j.jaad.2013.07.028
Tarhini, 2013, Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms of clinical management, Scientifica, 2013 [Article ID 857519], 19
Choi, 2013, How to recognize and manage ipilimumab-induced dermatologic adverse events, The Asco Post
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690
Hwang, 2016, Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort, J Am Acad Dermatol, 74, 455, 10.1016/j.jaad.2015.10.029
Stadler, 2014, New therapeutic options for advanced non-resectable malignant melanoma, Adv Med Sci, 60, 83, 10.1016/j.advms.2014.12.002
Joseph, 2015, Lichenoid dermatitis in three patients with metastatic melanoma treatment with anti-PD-1 therapy, Cancer Immunol Res, 3, 18, 10.1158/2326-6066.CIR-14-0134
Shi, 2016, Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherpay, JAMA Dermatol, 152, 1128, 10.1001/jamadermatol.2016.2226
Kato, 2015, Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma, J Eur Acad Dermatol Venereol, 30, e89, 10.1111/jdv.13336
Matsumura, 2016, Exacerbation of psoriasis during nivolumab therapy for metastaticn melanoma, Acta Derm Venereol, 96, 259, 10.2340/00015555-2212
Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 355, 2455, 10.1056/NEJMoa1200694
McDermott, 2016, Atezolizumab, an anti-programed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study, J Clin Oncol, 34, 833, 10.1200/JCO.2015.63.7421
Margolin, 2016, The promise of molecularly targeted and immunotherapy for advanced melanoma, Curr Treat Options Oncol, 17, 48, 10.1007/s11864-016-0421-5
Yun, 2016, Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systemic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials, Cancer Med, 5, 1481, 10.1002/cam4.732